Drug Profile
Gontivimab - Ablynx
Alternative Names: ALX-0171; Anti-RSV nanobody; VR 465Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ablynx
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 19 Mar 2019 Ablynx withdraws a phase II trial prior to enrolment in Respiratory syncytial virus infections (In infants) in Australia, Belgium and Spain as the compny stopped development of ALX 0171 (NCT03468829)
- 31 Dec 2018 Discontinued - Phase-II for Respiratory syncytial virus infections (In infants) in United Kingdom, Hungary, Spain, Slovakia, Belgium, Australia, Bulgaria, Estonia, Israel, Latvia, Malaysia, Philippines, Poland, Thailand, Germany, Lithuania, Chile, Croatia, Croatia, Colombia, Czech Republic, South Africa, Brazil (Inhalation) before December 2018 (Sanofi pipeline, February 2019)
- 15 Nov 2018 Discontinued - Phase-II for Respiratory syncytial virus infections (In infants) in Japan (Inhalation) (NCT03418571)